# Vanda Pharmaceuticals Inc. (VNDA)

> Source: Nexqual · https://nexqual.com/VNDA · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Vanda Pharmaceuticals Inc. (VNDA), nexqual.com/VNDA" · informational, not investment advice.

**Price:** USD 4.24 (+0.47% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 4.22 · day 4.01–4.31 · 52w 4.01–9.94 · market cap $256M · NGM

## Key facts
- Analysts: Buy (mean 2.20 on a 1–5 scale) (5 analysts), mean target USD 11.75 (range 5.75–20).
- Total return with dividends: 1Y -19.5% vs S&P 500 +18.1%; 5Y -77.0% vs S&P 500 +85.1%.
- Next earnings: 2026-11-04, EPS estimate USD -0.68, revenue estimate $69.1M.

## Analysts
Consensus Buy (mean 2.20 on a 1–5 scale), 5 analysts; mean target USD 11.75 (low 5.75, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-05 | HC Wainwright & Co. | Reiterated | Buy | $20 |
| 2026-09-23 | Oppenheimer | Initiated | Outperform | $10 |
| 2026-08-10 | B. Riley Securities | Target lowered | Buy | $17 → $12 |
| 2026-08-10 | HC Wainwright & Co. | Target lowered | Buy | $21 → $20 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -19.5% | -77.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -19.6% | -25.4% |
| Volatility (annualized) | 78.6% | 55.8% |
| Max drawdown | -55.9% (Mar 2026→Oct 2026) | -81.5% (Oct 2021→Nov 2023) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/VNDA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt